Doctors worried about threat to supplies of animal insulin

BMJ 2002; 324 doi: (Published 19 January 2002) Cite this as: BMJ 2002;324:130
  1. Mark Hunter
  1. Leeds

    Fears that worldwide production of animal insulin could be put at risk by the proposed takeover of Brazilian manufacturer Biobras have been dismissed by the multinational pharmaceutical company involved in the buy-out.

    Novo Nordisk has “no plans for the discontinuation of production of animal insulin.” Nor will it halt Biobras's supply of source material to other companies that manufacture insulin, claimed Novo's executive vice president, Lars Jorgensen.

    Concerns over the bid, which has been accepted by the Biobras board and is currently under …

    View Full Text

    Sign in

    Log in through your institution